Vaccine for mycoplasma infection
Inventors
Matsuda, Kazuhiro • Ichiyama, Koji • Matsuda, Sachie • Sasaki, Yuko • Arakawa, Yoshichika • Harasawa, Ryo • Nishida, Yoshihiro • Katayama, Norio • Endo, Yasuo • Nomura, Nobuo
Assignees
National Institute of Infectious Diseases • M Bio Technology Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9539209-B2
Publication Date
2017-01-10
Expiration Date
Abstract
Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
Core Innovation
The invention provides mycoplasma-mimic particles comprising liposome particles that include at least one mycoplasma-specific lipid antigen as a liposome-constituting lipid component. The mycoplasma-mimic particles include at least one other antigenic substance on the surfaces of the liposome particles, and the antigenicity of each other antigenic substance is increased by adjuvant effects of the mycoplasma-specific lipid antigen.
In the mycoplasma-mimic particles, the liposome particles include at least one mycoplasma-specific glycolipid antigen as a liposome-constituting lipid component. The mycoplasma-specific glycolipid antigen is chemically or enzymatically synthesized, and then separated and purified.
The invention further includes administering a vaccine to suppress or treat a disease caused by a mycoplasma infection. The vaccine comprises mycoplasma-mimic particles as an active ingredient and a pharmaceutically acceptable excipient, and the administration is performed at least once to a human or an animal affected or suspected to be affected with the mycoplasma infection.
Claims Coverage
The independent claims cover two inventive features.
Mycoplasma-mimic particles with enhanced surface antigenicity via adjuvant effects
Mycoplasma-mimic particles comprising liposome particles including at least one mycoplasma-specific lipid antigen as a liposome-constituting lipid component and at least one other antigenic substance on the surfaces of the liposome particles, wherein the antigenicity of each of the at least one other antigenic substance increases by adjuvant effects of the mycoplasma-specific lipid antigen.
Vaccine administration method for suppressing or treating mycoplasma infection-caused disease with synthesized glycolipid antigens
A method of suppressing or treating a disease caused by a mycoplasma infection, comprising administering at least once to a human or an animal affected or suspected to be affected with the mycoplasma infection a vaccine comprising mycoplasma-mimic particles as an active ingredient and a pharmaceutically acceptable excipient, wherein the mycoplasma-mimic particles comprise liposome particles including at least one mycoplasma-specific glycolipid antigen as a liposome-constituting lipid component, and wherein the at least one mycoplasma-specific glycolipid antigen is chemically or enzymatically synthesized, and then separated and purified.
The claims center on mycoplasma-mimic liposome particles that use mycoplasma-specific lipid antigens to increase the antigenicity of other surface antigens through adjuvant effects, and on using such particles in a vaccine formulation for suppressing or treating disease caused by a mycoplasma infection, with mycoplasma-specific glycolipid antigens chemically or enzymatically synthesized and purified.
Stated Advantages
Provides strong humoral/cellular immunity with high safety.
Supports induction of mucosal IgA and interferon-b3 responses.
Enables preventing or treating mycoplasma infection.
Documented Applications
Preventing or treating mycoplasma infection, including vaccine use for mycoplasma-associated pneumonia, asthma/COPD chronic diseases, and rheumatic diseases such as rheumatoid arthritis.
Adjuvant potential in relation to influenza.
Applicability to other bacteria, including Helicobacter pylori-mimic particles.
Diagnosis/monitoring using ELISA antibody titers and mass-spectrometry quantitation of lipid antigens to guide treatment.
Interested in licensing this patent?